Navidea Biopharmaceuticals (NYSE:NAVB) Now Covered by StockNews.com

Investment analysts at StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a report issued on Monday. The firm set a “sell” rating on the stock.

Navidea Biopharmaceuticals Price Performance

NAVB opened at $0.04 on Monday. The firm has a market capitalization of $3.50 million, a PE ratio of -0.58 and a beta of 1.13. Navidea Biopharmaceuticals has a fifty-two week low of $0.02 and a fifty-two week high of $0.27. The company’s 50-day moving average is $0.04 and its 200 day moving average is $0.05.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.